NCT00042497View on ClinicalTrials.gov

Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

PHASE2SuspendedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2002

Conditions
Melanoma
Interventions
BIOLOGICAL

autologous dexosomes loaded with tumor-specific peptides

Sponsors

Lead Sponsor

Anosys
All Listed Sponsors
lead

Anosys

INDUSTRY

NCT00042497 - Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma | Biotech Hunter | Biotech Hunter